These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33627502)

  • 21. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
    Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
    Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
    Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; Al-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L
    Breast Cancer Res Treat; 2011 Jul; 128(2):357-68. PubMed ID: 20730598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
    Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
    Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
    Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
    Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OBHSA, a novel selective estrogen receptor degrader, overcomes tamoxifen resistance through cell cycle arrest and unfolded protein response-mediated apoptosis in breast cancer.
    Shen R; Zhou J; Xin L; Zhou HB; Huang J
    J Steroid Biochem Mol Biol; 2024 Nov; 244():106599. PubMed ID: 39147211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
    Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
    Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer.
    Shahmoradgoli M; Riazalhosseini Y; Haag D; Becker N; Hovestadt V; Heck S; Sinn HP; Schneeweiss A; Mannherz O; Sahin Ö; Lichter P
    Int J Cancer; 2013 Jun; 132(11):2714-9. PubMed ID: 23169272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
    Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
    J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
    Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen metabolite endoxifen interferes with the polyamine pathway in breast cancer.
    Thomas TJ; Thomas T; John S; Hsu HC; Yang P; Keinänen TA; Hyvönen MT
    Amino Acids; 2016 Oct; 48(10):2293-302. PubMed ID: 27438264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor.
    Coser KR; Wittner BS; Rosenthal NF; Collins SC; Melas A; Smith SL; Mahoney CJ; Shioda K; Isselbacher KJ; Ramaswamy S; Shioda T
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14536-41. PubMed ID: 19706540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
    Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
    J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.
    Wrobel K; Zhao YC; Kulkoyluoglu E; Chen KL; Hieronymi K; Holloway J; Li S; Ray T; Ray PS; Landesman Y; Lipka AE; Smith RL; Madak-Erdogan Z
    Mol Endocrinol; 2016 Oct; 30(10):1029-1045. PubMed ID: 27533791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.
    Nehra R; Riggins RB; Shajahan AN; Zwart A; Crawford AC; Clarke R
    FASEB J; 2010 Jun; 24(6):2040-55. PubMed ID: 20154269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
    Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
    Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells.
    Duan L; Calhoun S; Shim D; Perez RE; Blatter LA; Maki CG
    J Mol Cell Biol; 2021 Sep; 13(6):433-444. PubMed ID: 33755174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
    Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
    Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.